CRVS$16.74
$16.73
Chart
Performance
Key Stats
AI CRVS Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
HoldCorvus Pharmaceuticals shows potential in its clinical pipeline, but its financial health is challenged by consistent net losses and lack of revenue. Technical indicators are mixed, suggesting a holding pattern until further clarity on clinical trial results and revenue generation.
Thematic
Corvus Pharmaceuticals operates in the burgeoning biopharmaceutical sector, focusing on critical areas like immune cell function and cancer treatments. The company's development of novel therapies for conditions like atopic dermatitis, asthma, psoriasis, and fibrotic diseases taps into significant healthcare needs. However, the reliance on a few key drug candidates and the inherent risks in clinical development represent thematic headwinds.
Fundamental
Corvus Pharmaceuticals exhibits significant financial weaknesses, characterized by a complete absence of revenue, substantial operating expenses, and consistent net losses. While it has some cash reserves and manageable debt, its ability to fund ongoing operations and clinical trials without further dilution or debt issuance remains a concern. The lack of profitability and revenue generation makes traditional valuation metrics difficult to apply.
Technical
The stock is trading within its 52-week range and shows mixed signals across different timeframes. While some indicators suggest potential buying pressure, others indicate caution due to overbought conditions in shorter timeframes and a bearish sentiment on longer timeframes. Investors should watch for clear directional signals.
| Factor | Score |
|---|---|
| Biopharmaceutical Innovation | 80 |
| Market Growth Potential | 70 |
| Regulatory Landscape | 50 |
| Competitive Environment | 60 |
| Partnerships and Collaborations | 70 |
| Factor | Score |
|---|---|
| Valuation | 10 |
| Profitability | 5 |
| Growth | 5 |
| Balance Sheet Health | 70 |
| Cash Flow | 15 |
| Factor | Score |
|---|---|
| Trend Analysis | 50 |
| Momentum | 60 |
| Moving Averages | 40 |
| Volume Analysis | 55 |
| Support/Resistance | 65 |
AI Investing Checklist
Powered by LiveAIBullish Points (9)
Strong Short-Term Performance
The stock has shown significant positive performance over the short term, with a 5-day return of 7.27% and a 1-month return of 19.41%.
Exceptional Long-Term Growth
The stock has delivered a substantial 1-year return of 62.41%, significantly outperforming broader market indices and indicating strong investor confidence and growth.
Bearish Points (12)
Negative Earnings Per Share (EPS)
The company has consistently reported negative EPS on a trailing twelve months (TTM) basis (-1.03), indicating ongoing unprofitability which is a significant risk factor.
No Revenue Generation
The company reports zero revenue for multiple periods, which is highly unusual for a publicly traded entity and suggests a lack of commercial product or service.
Calendar
August 2025
8
Next Earnings Date
H: $-0.10
A: $-0.12
L: $-0.16
Profile
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell atopic dermatitis, asthma, psoriasis, and fibrotic diseases. It also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer. It has a license agreement with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in South San Francisco, California.
Seasonals
Price Target
15.20 USD
The 39 analysts offering 1 year price forecasts for CRVS have a max estimate of 24.00 and a min estimate of 11.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Direct competitor in immuno-oncology with pipeline assets targeting adenosine pathway (A2aR/CD73), a key focus for CRVS.
Weight: 90
A dominant force in the immuno-oncology landscape with Keytruda, making them a major market influence and potential partner/competitor.
Weight: 88
Another leading player in immuno-oncology with Opdivo and Yervoy, constantly seeking new therapies and targets.
Weight: 85
Strong and expanding oncology pipeline, particularly in immune-oncology and targeted therapies, actively pursuing partnerships and acquisitions.